1
|
Sinatra L, Bandolik JJ, Roatsch M, Sönnichsen M, Schoeder CT, Hamacher A, Schöler A, Borkhardt A, Meiler J, Bhatia S, Kassack MU, Hansen FK. Hydroxamic Acids Immobilized on Resins
(HAIRs): Synthese von Dual‐Target‐HDAC‐Inhibitoren und HDAC‐PROTACs. Angew Chem Int Ed Engl 2020. [DOI: 10.1002/ange.202006725] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
- Laura Sinatra
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Deutschland
| | - Jan J. Bandolik
- Institut für Pharmazeutische und Medizinische Chemie Heinrich-Heine-Universität Düsseldorf 40225 Düsseldorf Deutschland
| | - Martin Roatsch
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Deutschland
- Center for Biopharmaceuticals Department of Drug Design and Pharmacology University of Copenhagen Universitetsparken 2 2100 Copenhagen Denmark
| | - Melf Sönnichsen
- Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie Medizinische Fakultät Heinrich-Heine -Universität Düsseldorf Moorenstr. 5 40225 Düsseldorf Deutschland
| | - Clara T. Schoeder
- Center for Structural Biology Department of Chemistry Vanderbilt University Nashville TN 37221 USA
| | - Alexandra Hamacher
- Institut für Pharmazeutische und Medizinische Chemie Heinrich-Heine-Universität Düsseldorf 40225 Düsseldorf Deutschland
| | - Andrea Schöler
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Deutschland
| | - Arndt Borkhardt
- Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie Medizinische Fakultät Heinrich-Heine -Universität Düsseldorf Moorenstr. 5 40225 Düsseldorf Deutschland
| | - Jens Meiler
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Deutschland
- Center for Structural Biology Department of Chemistry Vanderbilt University Nashville TN 37221 USA
| | - Sanil Bhatia
- Klinik für Kinder-Onkologie, -Hämatologie und klinische Immunologie Medizinische Fakultät Heinrich-Heine -Universität Düsseldorf Moorenstr. 5 40225 Düsseldorf Deutschland
| | - Matthias U. Kassack
- Institut für Pharmazeutische und Medizinische Chemie Heinrich-Heine-Universität Düsseldorf 40225 Düsseldorf Deutschland
| | - Finn K. Hansen
- Institut für Wirkstoffentwicklung Medizinische Fakultät Universität Leipzig Brüderstraße 34 04103 Leipzig Deutschland
- Pharmazeutische und Zellbiologische Chemie Pharmazeutisches Institut Universität Bonn An der Immenburg 4 53121 Bonn Deutschland
| |
Collapse
|
2
|
Sinatra L, Bandolik JJ, Roatsch M, Sönnichsen M, Schoeder CT, Hamacher A, Schöler A, Borkhardt A, Meiler J, Bhatia S, Kassack MU, Hansen FK. Hydroxamic Acids Immobilized on Resins (HAIRs): Synthesis of Dual-Targeting HDAC Inhibitors and HDAC Degraders (PROTACs). Angew Chem Int Ed Engl 2020; 59:22494-22499. [PMID: 32780485 PMCID: PMC7756583 DOI: 10.1002/anie.202006725] [Citation(s) in RCA: 36] [Impact Index Per Article: 9.0] [Reference Citation Analysis] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/09/2020] [Revised: 07/30/2020] [Indexed: 12/15/2022]
Abstract
Inhibition of more than one cancer-related pathway by multi-target agents is an emerging approach in modern anticancer drug discovery. Here, based on the well-established synergy between histone deacetylase inhibitors (HDACi) and alkylating agents, we present the discovery of a series of alkylating HDACi using a pharmacophore-linking strategy. For the parallel synthesis of the target compounds, we developed an efficient solid-phase-supported protocol using hydroxamic acids immobilized on resins (HAIRs) as stable and versatile building blocks for the preparation of functionalized HDACi. The most promising compound, 3 n, was significantly more active in apoptosis induction, activation of caspase 3/7, and formation of DNA damage (γ-H2AX) than the sum of the activities of either active principle alone. Furthermore, to demonstrate the utility of our preloaded resins, the HAIR approach was successfully extended to the synthesis of a proof-of-concept proteolysis-targeting chimera (PROTAC), which efficiently degrades histone deacetylases.
Collapse
Affiliation(s)
- Laura Sinatra
- Institute for Drug Discovery, Medical FacultyLeipzig UniversityBrüderstraße 3404103LeipzigGermany
| | - Jan J. Bandolik
- Institute of Pharmaceutical and Medicinal ChemistryHeinrich-Heine-Universität Düsseldorf40225DüsseldorfGermany
| | - Martin Roatsch
- Institute for Drug Discovery, Medical FacultyLeipzig UniversityBrüderstraße 3404103LeipzigGermany
- Center for BiopharmaceuticalsDepartment of Drug Design and PharmacologyUniversity of CopenhagenUniversitetsparken 22100CopenhagenDenmark
| | - Melf Sönnichsen
- Department of Pediatric OncologyHematology and Clinical ImmunologyMedical FacultyHeinrich Heine University DüsseldorfMoorenstr. 540225DüsseldorfGermany
| | - Clara T. Schoeder
- Center for Structural BiologyDepartment of ChemistryVanderbilt UniversityNashvilleTN37221USA
| | - Alexandra Hamacher
- Institute of Pharmaceutical and Medicinal ChemistryHeinrich-Heine-Universität Düsseldorf40225DüsseldorfGermany
| | - Andrea Schöler
- Institute for Drug Discovery, Medical FacultyLeipzig UniversityBrüderstraße 3404103LeipzigGermany
| | - Arndt Borkhardt
- Department of Pediatric OncologyHematology and Clinical ImmunologyMedical FacultyHeinrich Heine University DüsseldorfMoorenstr. 540225DüsseldorfGermany
| | - Jens Meiler
- Institute for Drug Discovery, Medical FacultyLeipzig UniversityBrüderstraße 3404103LeipzigGermany
- Center for Structural BiologyDepartment of ChemistryVanderbilt UniversityNashvilleTN37221USA
| | - Sanil Bhatia
- Department of Pediatric OncologyHematology and Clinical ImmunologyMedical FacultyHeinrich Heine University DüsseldorfMoorenstr. 540225DüsseldorfGermany
| | - Matthias U. Kassack
- Institute of Pharmaceutical and Medicinal ChemistryHeinrich-Heine-Universität Düsseldorf40225DüsseldorfGermany
| | - Finn K. Hansen
- Institute for Drug Discovery, Medical FacultyLeipzig UniversityBrüderstraße 3404103LeipzigGermany
- Pharmaceutical and Cell Biological ChemistryPharmaceutical InstituteUniversity of BonnAn der Immenburg 453121BonnGermany
| |
Collapse
|
3
|
Chen R, Zhang M, Zhou Y, Guo W, Yi M, Zhang Z, Ding Y, Wang Y. The application of histone deacetylases inhibitors in glioblastoma. JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH : CR 2020; 39:138. [PMID: 32682428 PMCID: PMC7368699 DOI: 10.1186/s13046-020-01643-6] [Citation(s) in RCA: 50] [Impact Index Per Article: 12.5] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Subscribe] [Scholar Register] [Received: 04/29/2020] [Accepted: 07/13/2020] [Indexed: 12/14/2022]
Abstract
The epigenetic abnormality is generally accepted as the key to cancer initiation. Epigenetics that ensure the somatic inheritance of differentiated state is defined as a crucial factor influencing malignant phenotype without altering genotype. Histone modification is one such alteration playing an essential role in tumor formation, progression, and resistance to treatment. Notably, changes in histone acetylation have been strongly linked to gene expression, cell cycle, and carcinogenesis. The balance of two types of enzyme, histone acetyltransferases (HATs) and histone deacetylases (HDACs), determines the stage of histone acetylation and then the architecture of chromatin. Changes in chromatin structure result in transcriptional dysregulation of genes that are involved in cell-cycle progression, differentiation, apoptosis, and so on. Recently, HDAC inhibitors (HDACis) are identified as novel agents to keep this balance, leading to numerous researches on it for more effective strategies against cancers, including glioblastoma (GBM). This review elaborated influences on gene expression and tumorigenesis by acetylation and the antitumor mechanism of HDACis. Besdes, we outlined the preclinical and clinical advancement of HDACis in GBM as monotherapies and combination therapies.
Collapse
Affiliation(s)
- Rui Chen
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Mengxian Zhang
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
| | - Yangmei Zhou
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Wenjing Guo
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Ming Yi
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| | - Ziyan Zhang
- Cancer Center, Integrated Hospital of Traditional Chinese Medicine, Southern Medical University, Guangzhou, 510000, Guangdong, China
| | - Yanpeng Ding
- Department of Oncology, Zhongnan Hospital, Wuhan University, Wuhan, 430030, China
| | - Yali Wang
- Department of Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China
| |
Collapse
|
4
|
M'kacher R, Frenzel M, Al Jawhari M, Junker S, Cuceu C, Morat L, Bauchet AL, Stimmer L, Lenain A, Dechamps N, Hempel WM, Pottier G, Heidingsfelder L, Laplagne E, Borie C, Oudrhiri N, Jouni D, Bennaceur-Griscelli A, Colicchio B, Dieterlen A, Girinsky T, Boisgard R, Bourhis J, Bosq J, Mehrling T, Jeandidier E, Carde P. Establishment and Characterization of a Reliable Xenograft Model of Hodgkin Lymphoma Suitable for the Study of Tumor Origin and the Design of New Therapies. Cancers (Basel) 2018; 10:cancers10110414. [PMID: 30384446 PMCID: PMC6265845 DOI: 10.3390/cancers10110414] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/05/2018] [Revised: 10/25/2018] [Accepted: 10/26/2018] [Indexed: 01/16/2023] Open
Abstract
To identify the cells responsible for the initiation and maintenance of Hodgkin lymphoma (HL) cells, we have characterized a subpopulation of HL cells grown in vitro and in vivo with the aim of establishing a reliable and robust animal model for HL. To validate our model, we challenged the tumor cells in vivo by injecting the alkylating histone-deacetylase inhibitor, EDO-S101, a salvage regimen for HL patients, into xenografted mice. Methodology: Blood lymphocytes from 50 HL patients and seven HL cell lines were used. Immunohistochemistry, flow cytometry, and cytogenetics analyses were performed. The in vitro and in vivo effects of EDO-S101 were assessed. Results: We have successfully determined conditions for in vitro amplification and characterization of the HL L428-c subline, containing a higher proportion of CD30−/CD15− cells than the parental L428 cell line. This subline displayed excellent clonogenic potential and reliable reproducibility upon xenografting into immunodeficient NOD-SCID-gamma (−/−)(NSG) mice. Using cell sorting, we demonstrate that CD30−/CD15− subpopulations can gain the phenotype of the L428-c cell line in vitro. Moreover, the human cells recovered from the seventh week after injection of L428-c cells into NSG mice were small cells characterized by a high frequency of CD30−/CD15− cells. Cytogenetic analysis demonstrated that they were diploid and showed high telomere instability and telomerase activity. Accordingly, chromosomal instability emerged, as shown by the formation of dicentric chromosomes, ring chromosomes, and breakage/fusion/bridge cycles. Similarly, high telomerase activity and telomere instability were detected in circulating lymphocytes from HL patients. The beneficial effect of the histone-deacetylase inhibitor EDO-S101 as an anti-tumor drug validated our animal model. Conclusion: Our HL animal model requires only 103 cells and is characterized by a high survival/toxicity ratio and high reproducibility. Moreover, the cells that engraft in mice are characterized by a high frequency of small CD30−/CD15− cells exhibiting high telomerase activity and telomere dysfunction.
Collapse
Affiliation(s)
- Radhia M'kacher
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
- Cell Environment, Oncology Section, 75020 Paris, France.
| | - Monika Frenzel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Mustafa Al Jawhari
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Steffen Junker
- Institute of Biomedicine, University of Aarhus, DK-8000 Aarhus C, Denmark.
| | - Corina Cuceu
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Luc Morat
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Anne-Laure Bauchet
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Lev Stimmer
- Platform for Experimental Pathology PathEX/CRC MIRCen/CEA-INSERM, University Paris-Saclay, 92265 Fontenay aux Rroses, France.
| | - Aude Lenain
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Nathalie Dechamps
- Platform for Cell Sorting, CEA, iRCM, 92265 Fontenay aux Roses, France.
| | - William M Hempel
- Radiobiology and Oncology Laboratory, CEA, iRCM, University Paris-Saclay, 92 265 Fontenay aux Roses, France.
| | - Geraldine Pottier
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | | | | | - Claire Borie
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Noufissa Oudrhiri
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | - Dima Jouni
- APHP-Hopital Paul Brousse Université Paris Sud/ESteam Paris Inserm UMR 935, 94800 Villejuif, France.
| | | | - Bruno Colicchio
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Alain Dieterlen
- IRIMAS, Institut de Recherche en Informatique, Mathématiques, Automatique et Signal, Université de Haute-Alsace, 68093 Mulhouse, France.
| | - Theodore Girinsky
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Raphael Boisgard
- Laboratoire d'Imagerie Moléculaire Expérimentale Groupe d'Imagerie du Petit Animal CEA/DSV/I2BM/SHFJ/U1023, University Paris-Saclay, 91400 Orsay, France.
| | - Jean Bourhis
- Department of Radiation Oncology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| | - Jacques Bosq
- Departement of Anapathology, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Vilejuif, France.
| | | | - Eric Jeandidier
- Department of Genetic, Groupe Hospitalier de la Région de Mulhouse Sud-Alsace, 68093 Mulhouse, France.
| | - Patrice Carde
- Department of Medicine, Gustave Roussy Cancer Campus, University Paris-Saclay, 94805 Villejuif, France.
| |
Collapse
|